{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:55:58Z","timestamp":1780469758663,"version":"3.54.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> With the advent of aging society of China, fundus diseases related to pathological neovascularization, including age-related macular degeneration (AMD), diabetic macular edema (DME), and pathological myopia (PM), have become an increasingly serious medical and health problems. As effective drugs of the treatment, conbercept and ranibizumab have been commonly used and covered by the national basic medical insurance in China. However, the pharmacoeconomic evaluation of conbercept vs. ranibizumab for DME and PM remains lacking. This study would assess the cost-effectiveness of conbercept and ranibizumab for the treatment of AMD, DME, and PM from the perspective of Chinese payers.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A Markov chain model was constructed based on the visual conditions of the patient indicated by the number of letters in best corrected visual acuity (BCVA). We conducted models based on real-world scenario to calculate the cost per the quality-adjusted life-year (QALY) gained. A 1-year cycle length and a 10-year simulation treatment were applied and the number of injections of conbercept and ranibizumab was assumed to the average number within 10 years. Transition probabilities, costs, utility data, and other parameters were obtained from literature searches. A 3.5% discounting rate was applied for both the costs and utilities.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The incremental cost-effectiveness ratios (ICERs) were more favorable for conbercept than ranibizumab in treatment of AMD, DME, and PM, with associated ICER of 66,669 renminbi (RMB), \u2212258,813 RMB, and \u2212373,185 RMB per QALY gained. Compared with ranibizumab, the incremental effectiveness of conbercept in treatment of AMD, DME, and PM was \u22120.665 QALYs, 0.215 QALYs, and 0.029 QALYs, respectively. The sensitivity analysis showed the same findings, although the ICER is sensitive to the costs of this program.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Under the current Chinese healthcare setting, conbercept is suitable and cost-effective in treatment of AMD, DME, and PM compared with ranibizumab.<\/jats:p>","DOI":"10.3389\/fmed.2021.750132","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T08:29:27Z","timestamp":1638433767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model"],"prefix":"10.3389","volume":"8","author":[{"given":"Zhuang","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangda","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1350-9462(98)00025-1","article-title":"The prevalence of age-related maculopathy by geographic region and ethnicity","volume":"18","author":"Klein","year":"1999","journal-title":"Prog Retin Eye Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1076\/opep.11.2.67.28158","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull World Health Organ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet (London, England)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ceo.12999","article-title":"Diabetic macular oedema: evidence-based treatment recommendations for Asian countries","volume":"46","author":"Cheung","year":"2018","journal-title":"Clin Exp Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22608\/APO.2017511","article-title":"Diabetic retinopathy in the Asia-Pacific","volume":"7","author":"Chua","year":"2018","journal-title":"Asia Pac J Ophthalmol (Phila)."},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.21037\/atm.2018.11.20","article-title":"VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?","volume":"6","author":"Alexander","year":"2018","journal-title":"Ann Transl Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40259-014-0106-1","article-title":"EXTEND II: an open-label phase III multicentre study to evaluate efficacy and safety of ranibizumab in Chinese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"28","author":"Zhao","year":"2014","journal-title":"BioDrugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","article-title":"Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study","volume":"121","author":"Li","year":"2014","journal-title":"Ophthalmology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12886-018-0807-1","article-title":"Conbercept for patients with age-related macular degeneration: a systematic review","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.21037\/atm-20-1334","article-title":"Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration","volume":"8","author":"Chen","year":"2020","journal-title":"Ann Transl Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study","volume":"197","author":"Liu","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318690.","article-title":"Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study","author":"Liu","year":"2021","journal-title":"Br J Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","article-title":"Efficacy and safety of ranibizumab 05 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study","volume":"257","author":"Li","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B20","volume-title":"Pharmacoeconomics Study of Lumitin","author":"Xuan","year":"2019"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","article-title":"Ranibizumab versus verteporfin photodynamic therapy in asian patients with myopic choroidal neovascularization: brilliance, a 12-month, randomized, double-masked study","volume":"39","author":"Chen","year":"2019","journal-title":"Retina."},{"key":"B22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1524-4733.2009.00527.x","article-title":"Valuing condition-specific health states using simulation contact lenses","volume":"12","author":"Czoski-Murray","year":"2009","journal-title":"Value Health."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0201399","DOI":"10.1371\/journal.pone.0201399","article-title":"Utility values for age-related macular degeneration patients in Korea","volume":"13","author":"Choi","year":"2018","journal-title":"PLoS ONE."},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.12010\/j.issn.1673-5846.2018.09.005","article-title":"Pharmacoeconomic evaluation of conbercept and rezumumab in the treatment of age-related macular degeneration","volume":"13","author":"Aixia","year":"2018","journal-title":"China J Pharm Econ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/eye.2017.187","article-title":"Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study","volume":"32","author":"Cui","year":"2018","journal-title":"Eye (Lond)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e19007","DOI":"10.1097\/MD.0000000000019007","article-title":"Different conbercept injection strategies for the treatment of exudative age-related macular degeneration: A retrospective cohort study","volume":"99","author":"Gao","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.18240\/ijo.2019.02.11","article-title":"Intravitreal conbercept injection for neovascular age-related macular degeneration","volume":"12","author":"Wu","year":"2019","journal-title":"Int J Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.18240\/ijo.2021.03.14","article-title":"Real-world outcomes of two-year Conbercept therapy for diabetic macular edema","volume":"14","author":"Cheng","year":"2021","journal-title":"Int J Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/02713683.2017.1379542","article-title":"One-year outcome of conbercept therapy for diabetic macular edema","volume":"43","author":"Li","year":"2018","journal-title":"Curr Eye Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12886-019-1131-0","article-title":"Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment","volume":"19","author":"Xu","year":"2019","journal-title":"BMC Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2143082","DOI":"10.1155\/2016\/2143082","article-title":"Intravitreal conbercept injection with and without grid laser photocoagulation in the treatment of diffuse diabetic macular edema in real-life clinical practice","volume":"2016","author":"Xu","year":"2016","journal-title":"J Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12886-017-0554-8","article-title":"Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study","volume":"17","author":"Xu","year":"2017","journal-title":"BMC Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3969\/j.issn.1674-9006.2017.04.013","article-title":"Observation of the curative effect of anti-VEG drug Conbercept in the treatment of choroidal neovascularization in pathological myopia","volume":"7","author":"Chen","year":"2017","journal-title":"J Chin Ophthalmol Otorhinolaryngol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina."},{"key":"B35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/aos.12091","article-title":"A three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs","volume":"92","author":"Frennesson","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"405724","DOI":"10.1155\/2011\/405724","article-title":"One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study","volume":"2011","author":"Hjelmqvist","year":"2011","journal-title":"J Ophthalmol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye (Lond)."},{"key":"B39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000350238","article-title":"Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration","volume":"230","author":"Muniraju","year":"2013","journal-title":"Ophthalmologica."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2147\/OPTH.S49385","article-title":"Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study","volume":"7","author":"Rakic","year":"2013","journal-title":"Clin Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajo.2016.09.002","article-title":"Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting","volume":"172","author":"Patrao","year":"2016","journal-title":"Am J Ophthalmol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bjophthalmol-2016-309313","article-title":"The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema","volume":"101","author":"Egan","year":"2017","journal-title":"Br J Ophthalmol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s13300-018-0513-2","article-title":"Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional, multicenter study in Germany","volume":"9","author":"Ziemssen","year":"2018","journal-title":"Diabetes Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s10792-018-0970-7","article-title":"Real-life experience of ranibizumab for diabetic macular edema in Taiwan","volume":"39","author":"Tsai","year":"2019","journal-title":"Int Ophthalmol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0233595","DOI":"10.1371\/journal.pone.0233595","article-title":"Effectiveness and safety of ranibizumab 05 mg in treatment-na\u00efve patients with diabetic macular edema: results from the real-world global LUMINOUS study","volume":"15","author":"Mitchell","year":"2020","journal-title":"PLoS ONE."},{"key":"B46","doi-asserted-by":"publisher","first-page":"925","DOI":"10.13389\/j.cnki.rao.2018.0219","article-title":"Efficacy of intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to pathological myopia","volume":"38","author":"Sun","year":"2018","journal-title":"Recent Adv Ophthalmol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1111\/aos.13632","article-title":"Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia","volume":"97","author":"Yan","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"A421","DOI":"10.1016\/j.jval.2015.09.558","article-title":"Cost-effectiveness analysis of conbercept versus ranibizumab for the treatment of age-related macular degeneration in China","volume":"18","author":"Zhao","year":"2015","journal-title":"Value Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/IMCRJ.S191654","article-title":"Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis(\u00ae))","volume":"13","author":"Horowitz","year":"2020","journal-title":"Int Med Case Rep J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1023\/A:1025643303914","article-title":"Epidemiology of age-related maculopathy: a review","volume":"18","author":"van Leeuwen","year":"2003","journal-title":"Eur J Epidemiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.ophtha.2009.10.007","article-title":"The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis","volume":"117","author":"Kawasaki","year":"2010","journal-title":"Ophthalmology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10384-016-0496-3","article-title":"Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study","volume":"61","author":"Yang","year":"2017","journal-title":"Jpn J Ophthalmol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00417-011-1889-0","article-title":"Recent trends in the management of maculopathy secondary to pathological myopia","volume":"250","author":"Mitry","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"236","DOI":"10.17925\/EOR.2012.06.04.236","article-title":"Long-term therapies for diabetic macular edema","volume":"6","author":"Lotery","year":"2012","journal-title":"Eur Ophthalmic Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-021-04028-x","article-title":"Association of periodontitis and diabetic macular edema in various stages of diabetic retinopathy","author":"Lindner","year":"2021","journal-title":"Clin Oral Investig."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.2337\/diacare.27.10.2568","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Rathmann","year":"2004","journal-title":"Diabetes Care"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e1003434","DOI":"10.1371\/journal.pmed.1003434","article-title":"Health system interventions for adults with type 2 diabetes in low- and middle-income countries: a systematic review and meta-analysis","volume":"17","author":"Flood","year":"2020","journal-title":"PLoS Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.orcp.2017.10.005","article-title":"Dynamic status of metabolically healthy overweight\/obesity and metabolically unhealthy and normal weight and the risk of type 2 diabetes mellitus: a cohort study of a rural adult Chinese population","volume":"12","author":"Wang","year":"2018","journal-title":"Obes Res Clin Pract."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0167123","DOI":"10.1371\/journal.pone.0167123","article-title":"Effects of a community-based healthy lifestyle intervention program (Co-HELP) among Adults with prediabetes in a developing country: a quasi-experimental study","volume":"11","author":"Ibrahim","year":"2016","journal-title":"PLoS ONE."},{"key":"B63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica."},{"key":"B64","doi-asserted-by":"publisher","first-page":"743","DOI":"10.18553\/jmcp.2021.27.6.743","article-title":"Brolucizumab vs. aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis","volume":"27","author":"Yu","year":"2021","journal-title":"J Manag Care Spec Pharm."},{"key":"B65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.vhri.2019.09.007","article-title":"Cost-minimization analysis of ranibizumab versus aflibercept for treating saudi patients with visual impairment owing to age-related macular degeneration or diabetic macular edema","volume":"22","author":"El-Dahiyat","year":"2020","journal-title":"Value Health Reg Issues."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta25380","article-title":"Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT","volume":"25","author":"Hykin","year":"2021","journal-title":"Health Technol Assess."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.750132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T08:29:34Z","timestamp":1638433774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.750132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":66,"alternative-id":["10.3389\/fmed.2021.750132"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.750132","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"article-number":"750132"}}